Formulate saRNA into Lipid Nanoparticle (LNP) formulation with iL2V02 composition, Synthesize and characterize 3 of each saRNA and mRNA

The University’s research on development of vaccines against viral infectious diseases requires specialized expertise and saRNA related technology to carry out delivery, immunogenicity and minimal reactogenicity. Cytiva’s (formerly Precision Nanosystems) technology are essential for the development of saRNA and mRNA and manufacturing of LNP formulations and are critical for the departmental research and advancements in the field.